Moderna Inc (NASDAQ:MRNA) insider Tal Zvi Zaks sold 20,000 shares of Moderna stock in a transaction on Monday, July 27th. The stock was sold at an average price of $78.73, for a total value of $1,574,600.00. Following the completion of the sale, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $787,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tal Zvi Zaks also recently made the following trade(s):

  • On Monday, July 20th, Tal Zvi Zaks sold 20,000 shares of Moderna stock. The shares were sold at an average price of $83.50, for a total value of $1,670,000.00.
  • On Monday, July 13th, Tal Zvi Zaks sold 20,000 shares of Moderna stock. The shares were sold at an average price of $69.94, for a total value of $1,398,800.00.
  • On Tuesday, July 7th, Tal Zvi Zaks sold 62,688 shares of Moderna stock. The shares were sold at an average price of $59.26, for a total value of $3,714,890.88.
  • On Tuesday, June 30th, Tal Zvi Zaks sold 39,752 shares of Moderna stock. The shares were sold at an average price of $64.00, for a total value of $2,544,128.00.
  • On Tuesday, June 23rd, Tal Zvi Zaks sold 39,752 shares of Moderna stock. The shares were sold at an average price of $63.71, for a total value of $2,532,599.92.
  • On Tuesday, June 16th, Tal Zvi Zaks sold 39,752 shares of Moderna stock. The shares were sold at an average price of $63.76, for a total value of $2,534,587.52.
  • On Tuesday, June 2nd, Tal Zvi Zaks sold 98,956 shares of Moderna stock. The shares were sold at an average price of $58.32, for a total value of $5,771,113.92.
  • On Tuesday, May 26th, Tal Zvi Zaks sold 125,044 shares of Moderna stock. The shares were sold at an average price of $66.54, for a total value of $8,320,427.76.
  • On Tuesday, May 5th, Tal Zvi Zaks sold 4,770 shares of Moderna stock. The shares were sold at an average price of $50.48, for a total value of $240,789.60.

NASDAQ:MRNA opened at $74.10 on Friday. The company has a market capitalization of $27.51 billion, a P/E ratio of -49.40 and a beta of 0.67. Moderna Inc has a 12 month low of $11.54 and a 12 month high of $95.21. The business’s 50-day moving average is $69.03 and its 200 day moving average is $44.88.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. The company had revenue of $8.39 million for the quarter, compared to the consensus estimate of $18.17 million. Moderna had a negative return on equity of 37.49% and a negative net margin of 963.84%. Equities research analysts predict that Moderna Inc will post -1.41 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. CVA Family Office LLC raised its position in Moderna by 40.0% during the second quarter. CVA Family Office LLC now owns 1,400 shares of the company’s stock valued at $90,000 after purchasing an additional 400 shares during the period. Valeo Financial Advisors LLC raised its position in Moderna by 23.1% during the second quarter. Valeo Financial Advisors LLC now owns 2,215 shares of the company’s stock valued at $142,000 after purchasing an additional 415 shares during the period. Corbenic Partners LLC purchased a new stake in Moderna during the second quarter valued at approximately $32,000. Weaver Consulting Group purchased a new stake in Moderna during the second quarter valued at approximately $48,000. Finally, D Orazio & Associates Inc. purchased a new stake in Moderna during the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 52.09% of the company’s stock.

Several analysts have issued reports on MRNA shares. Morgan Stanley boosted their price target on Moderna from $37.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Bank of America dropped their price objective on Moderna from $80.00 to $75.00 in a research note on Wednesday, June 3rd. SunTrust Banks initiated coverage on Moderna in a research note on Monday, July 27th. They issued a “buy” rating and a $120.00 price objective for the company. JPMorgan Chase & Co. lowered Moderna from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $60.00 to $89.00 in a research note on Monday, July 20th. They noted that the move was a valuation call. Finally, Argus initiated coverage on Moderna in a research note on Tuesday, June 30th. They issued a “buy” rating and a $80.00 price objective for the company. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $88.78.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More: Why Dividend Stocks May Be Right for You

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.